AEMD vs. NMTC, NXL, COCH, SURG, POCI, IRIX, DRIO, XAIR, PTHL, and CODX
Should you be buying Aethlon Medical stock or one of its competitors? The main competitors of Aethlon Medical include NeuroOne Medical Technologies (NMTC), Nexalin Technology (NXL), Envoy Medical (COCH), SurgePays (SURG), Precision Optics (POCI), IRIDEX (IRIX), DarioHealth (DRIO), Beyond Air (XAIR), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), and Co-Diagnostics (CODX). These companies are all part of the "medical equipment" industry.
Aethlon Medical vs.
NeuroOne Medical Technologies (NASDAQ:NMTC) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
NeuroOne Medical Technologies has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Aethlon Medical has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.
In the previous week, NeuroOne Medical Technologies' average media sentiment score of 0.50 beat Aethlon Medical's score of -0.50 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.
Aethlon Medical has lower revenue, but higher earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks.
Aethlon Medical has a consensus target price of $7.00, indicating a potential upside of 954.53%. Given Aethlon Medical's stronger consensus rating and higher possible upside, analysts clearly believe Aethlon Medical is more favorable than NeuroOne Medical Technologies.
Aethlon Medical has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -356.76%. Aethlon Medical's return on equity of -160.36% beat NeuroOne Medical Technologies' return on equity.
Aethlon Medical received 155 more outperform votes than NeuroOne Medical Technologies when rated by MarketBeat users. However, 71.59% of users gave NeuroOne Medical Technologies an outperform vote while only 51.29% of users gave Aethlon Medical an outperform vote.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are held by institutional investors. 7.5% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 1.1% of Aethlon Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Aethlon Medical beats NeuroOne Medical Technologies on 11 of the 17 factors compared between the two stocks.
Get Aethlon Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aethlon Medical Competitors List
Related Companies and Tools
This page (NASDAQ:AEMD) was last updated on 1/21/2025 by MarketBeat.com Staff
